HK Stock Market Move | REMEGEN(09995) rose over 3% in late trading; analysis results of the Chinese Phase III clinical study of Telitacicept for the treatment of gMG were announced at the AANEM Annual Meeting.

REMEGEN(09995) rose over 3% in late trading, up 3.01% as of press time, at HK$77.05, with a turnover of HK$219 million. On the news front, according to REMEGEN's official WeChat account, on September 29, a latest post-hoc analysis result of the Chinese Phase III clinical study of REMEGEN's Telitacicept for the treatment of generalized myasthenia gravis (gMG) was publicly released as an oral presentation during the Myasthenia Gravis Foundation of America (MGFA) Scientific Session at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. Recently, Vor Bio announced that the global Phase III clinical study (UPSTREAM MG) of Telitacicept for the treatment of gMG has completed patient enrollment, and topline results for the study's 24-week primary endpoint are expected to be announced in the first half of 2027. Meanwhile, Vor Bio plans to initiate its global Phase III registrational clinical study (UPSTREAM oMG) for the treatment of ocular myasthenia gravis (oMG), with the first patient expected to complete enrollment and dosing in the first half of 2027. Domestically, the gMG indication of Telitacicept was approved for marketing in May 2025, and the Phase III clinical study for the treatment of oMG has completed patient enrollment, with data expected to be read out in the first half of 2027.